Reata Pharmaceuticals Inc expected to post a loss of $2.18 a share - Earnings Preview

Reata Pharmaceuticals

04/11/2022 19:35

* Reata Pharmaceuticals Inc  RETA.OQ   RETA.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
8. 
    * The Plano Texas-based  company is expected to report  a
91.3% decrease in revenue to $645.25 thousand from $7.39 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Reata
Pharmaceuticals Inc
is for a loss of $2.18 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $49​, above​ its last closing price
of $32.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -2.03       -2.02      -2.02     Met     0.1
 Mar. 31 2022  -2.17       -2.17      -2.03     Beat    6.5
 Dec. 31 2021  -2.30       -2.31      -2.35     Missed  -1.8​
 Sep. 30 2021  -2.16       -2.16      -1.97     Beat    9
 ​​Jun.        -2.02       -2.06      -2.00     Beat    2.8
 30 2021                                                
 Mar. 31 2021  -2.08       -2.10      -1.86     Beat    11.3​
 Dec. 31 2020  -2.15       -2.16      -1.90     Beat    11.9
 Sep. 30 2020  -1.99       -1.98      -1.94     Beat    1.9
 This summary was machine generated November 4 at 19:35 GMT.  All
figures in US dollars  unless otherwise stated